Financials data is unavailable for this security.
View more
Year on year CH Biotech R&D Co Ltd had little change in net income (from 465.42m to 463.29m) despite revenues that grew 5.63% from 1.43bn to 1.51bn. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 24.48% to 25.68%.
Gross margin | 82.95% |
---|---|
Net profit margin | 25.30% |
Operating margin | 31.87% |
Return on assets | 11.07% |
---|---|
Return on equity | 15.93% |
Return on investment | 13.37% |
More ▼
Cash flow in TWDView more
In 2023, CH Biotech R&D Co Ltd increased its cash reserves by 77.34%, or 409.91m. The company earned 659.15m from its operations for a Cash Flow Margin of 43.51%. In addition the company used 142.89m on investing activities and also paid 106.60m in financing cash flows.
Cash flow per share | 5.55 |
---|---|
Price/Cash flow per share | 14.80 |
Book value per share | 25.46 |
---|---|
Tangible book value per share | 25.40 |
More ▼
Balance sheet in TWDView more
Current ratio | 1.39 |
---|---|
Quick ratio | 1.28 |
Total debt/total equity | 0.279 |
---|---|
Total debt/total capital | 0.2181 |
More ▼
Growth rates in TWD
Year on year, growth in dividends per share increased 5.41% while earnings per share excluding extraordinary items growth only marginally increased 0.30%. The positive trend in dividend payments is noteworthy since only some companies in the Chemical Manufacturing industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg) | 3.40% |
---|---|
Div growth rate (5 year) | 45.93% |
Payout ratio (TTM) | 96.80% |
EPS growth(5 years) | 10.24 |
---|---|
EPS (TTM) vs TTM 1 year ago | -- |
More ▼